Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 [Thoracic Oncology]
Conclusion
Compared with chemotherapy, crizotinib demonstrated a significantly higher IC-DCR in patients with tBM. Improvements in IC-TTP were not statistically significant in patients with or without tBM, although sensitivity to detect treatment differences in or between the two subgroups was low.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Solomon, Cappuzzo, Felip, Blackhall, Costa, Kim, Nakagawa, Wu, Mekhail, Paolini, Tursi, Usari, Wilner, Selaru, Mok Tags: Chemotherapy Thoracic Oncology Source Type: research
More News: Alimta | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Statistics | Study